Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H21ClN6O |
Molecular Weight | 420.895 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC1=NC(Cl)=C(C=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=NN4
InChI
InChIKey=FQZSMTSTFMNWQF-UHFFFAOYSA-N
InChI=1S/C22H21ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,14H,2-3,8,13H2,1H3,(H,25,26,27,28)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P17252 Gene ID: 5578.0 Gene Symbol: PRKCA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19687351 |
|||
Target ID: P05771|||Q9UE50 Gene ID: 5579.0 Gene Symbol: PRKCB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19687351 |
|||
Target ID: P37231|||Q15179 Gene ID: 5468.0 Gene Symbol: PPARG Target Organism: Homo sapiens (Human) |
17.1 µM [EC50] |
PubMed
Title | Date | PubMed |
---|---|---|
Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179. | 2005 Sep 20 |
|
Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. | 2006 Mar |
|
EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis. | 2007 May |
|
Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. | 2009 Oct |
|
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation. | 2009 Oct |
|
Protein kinase C-inhibiting properties of the losartan metabolite EXP3179 make the difference. | 2009 Oct |
|
Losartan metabolite EXP3179: an AT1-receptor-independent treatment strategy for patients with the metabolic syndrome? | 2009 Oct |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1370495
Created by
admin on Sat Dec 16 08:22:11 GMT 2023 , Edited by admin on Sat Dec 16 08:22:11 GMT 2023
|
PRIMARY | |||
|
114798-36-6
Created by
admin on Sat Dec 16 08:22:11 GMT 2023 , Edited by admin on Sat Dec 16 08:22:11 GMT 2023
|
PRIMARY | |||
|
DTXSID80150855
Created by
admin on Sat Dec 16 08:22:11 GMT 2023 , Edited by admin on Sat Dec 16 08:22:11 GMT 2023
|
PRIMARY | |||
|
9802264
Created by
admin on Sat Dec 16 08:22:11 GMT 2023 , Edited by admin on Sat Dec 16 08:22:11 GMT 2023
|
PRIMARY | |||
|
KJ52CU0VV6
Created by
admin on Sat Dec 16 08:22:11 GMT 2023 , Edited by admin on Sat Dec 16 08:22:11 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD